BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37029241)

  • 21. Palbociclib combined with endocrine therapy in heavily pretreated HR
    Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F
    Breast; 2020 Dec; 54():286-292. PubMed ID: 33242755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
    Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
    Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
    Fung S; Blair HA
    Target Oncol; 2023 Mar; 18(2):287-294. PubMed ID: 36826463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
    Rugo HS; Dieras V; Cortes J; Patt D; Wildiers H; O'Shaughnessy J; Zamora E; Yardley DA; Carter GC; Sheffield KM; Li L; Andre VAM; Li XI; Frenzel M; Huang YJ; Dickler MN; Tolaney SM
    Breast Cancer Res Treat; 2020 Nov; 184(1):161-172. PubMed ID: 32789591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
    J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
    Yang J; Zhao B; Ling X; Li D; Zhao J; Lv Y; Wang G; Liu X; Li N; Yang J
    BMC Cancer; 2023 Jan; 23(1):103. PubMed ID: 36717797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
    Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
    Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
    Front Oncol; 2021; 11():810023. PubMed ID: 35223458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
    Gavilá J; De La Haba J; Bermejo B; Rodríguez-Lescure Á; Antón A; Ciruelos E; Brunet J; Muñoz-Couselo E; Santisteban M; Rodríguez Sánchez CA; Santaballa A; Sánchez Rovira P; García Sáenz JÁ; Ruiz-Borrego M; Guerrero-Zotano AL; Huerta M; Cotes-Sanchís A; Lao Romera J; Aguirre E; Cortés J; Llombart-Cussac A
    Clin Transl Oncol; 2020 Mar; 22(3):420-428. PubMed ID: 31203575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
    Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
    Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
    Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
    Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.